Related Experiment Video
Updated: Sep 19, 2025

Visualization of Pseudomonas aeruginosa within the Sputum of Cystic Fibrosis Patients
Published on: July 16, 2020
A case of non-HIV pneumocystis pneumonia in a patient with cirrhosis-associated immune dysfunction
Kai Miyamoto1, Yoshihito Uchida2, Shohei Tsuji2
1Clinical Training Center, Saitama Medical University Hospital, Saitama, Japan.
Abstract:
A 55-year-old man with a 13-year history of alcohol-related cirrhosis was admitted for the management of refractory ascites. On day 4 of hospitalization, he developed dyspnea, and chest computed tomography (CT) revealed ground-glass opacities and reticular shadows in both lungs, predominantly in the left upper lobe. Aspiration pneumonia was initially suspected, and cefmetazole was administered. However, by day 11, his respiratory status deteriorated, with SpO₂ dropping to 90%. A follow-up chest CT showed progression of bilateral ground-glass opacities. Further testing revealed an elevated β-D-glucan level of 142.5 pg/mL and KL-6 level of 1.770 U/mL, along with a positive sputum PCR for Pneumocystis jirovecii, confirming a diagnosis of pneumocystis pneumonia (PCP). As human immunodeficiency virus (HIV) testing was negative, he was diagnosed with non-HIV PCP. Despite treatment with trimethoprim-sulfamethoxazole and hydrocortisone, he died on day 17. Notably, his peripheral lymphocyte count was below 500/μL before admission, suggesting that cirrhosis-associated immune dysfunction (CAID) contributed to his susceptibility to non-HIV PCP. This case highlights the importance of monitoring peripheral lymphocyte counts in patients with advanced liver cirrhosis, as CAID may increase the risk of life-threatening infections such as non-HIV PCP.
More Related Videos
07:21Processing of Bronchoalveolar Lavage Fluid and Matched Blood for Alveolar Macrophage and CD4+ T-cell Immunophenotyping and HIV Reservoir Assessment
Published on: June 23, 2019
10:12Establishment of the Dual Humanized TK-NOG Mouse Model for HIV-associated Liver Pathogenesis
Published on: September 11, 2019
Related Concept Videos
Pneumonia I: Introduction
Risk Factors
Various factors influence the likelihood of developing pneumonia. Age plays a crucial role, with infants, children under two, and individuals over 65 at increased risk due to their...
Pulmonary Tuberculosis I
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
Immunodeficiency Diseases
There are three main causes of immunodeficiency...
Pneumonia II: Pathophysiology
Pneumonia III: Complications and Assessment
Pneumonia IV: Management
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include: